

Michigan Pharmacy and Therapeutics Committee
Asthma-Allergy Workgroup
April 2008

Following review and discussion, the workgroup recommends to the full Committee for discussion at the June meeting the following:

Inhaled Anticholinergics

No change to the current classification of the drug products

Antihistamines-2nd Generation

Change fexofenadine to requiring prior authorization

Remove prior authorization from cetirizine

Other drug products to maintain current classification

Beta Adrenergics-Short Acting

No change to the current classification of the drug products

Beta Adrenergics-Long Acting

No change to the current classification of the drug products

Beta Adrenergics for Nebulizers

No change to the current classification of the drug products

Beta Adrenergic/Corticosteroid Inhaler Combinations

No change to the current classification of the drug products

Inhaled Glucocorticoids

Change Pulmicort Flexihaler to requiring prior authorization

No change to the current classification of the other drug products

Leukotriene Inhibitors

No change to the current classification of the drug products

Nasal Steroids

No change to the current classification of the drug products